Used in targeted cancer therapies, particularly for tumors overexpressing FGFR4 (CD334), such as hepatocellular carcinoma, rhabdomyosarcoma, and certain breast cancers. The antibody binds specifically to FGFR4, blocking receptor activation and downstream signaling pathways involved in cell proliferation and survival. It is also employed in research settings to study FGFR4's role in tumor progression and resistance mechanisms. In immunotherapy development, this reference antibody serves as a template for engineering bispecific antibodies or antibody-drug conjugates aimed at enhancing T-cell mediated killing of FGFR4-positive cancer cells. Additionally, it supports diagnostic applications by enabling detection and quantification of FGFR4 expression in tissue samples.